Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 known ✓ | P32297 | 2/20 | 0.36 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.36 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.35 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7237491 | 1.00 | HCAR2 (0.39) | HCAR2ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5301644 | 1.00 | HCAR2 (0.39) | HCAR2ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL197006 | 0.98 | — | — | |
| SCHEMBL197007 | 0.98 | — | — | |
| SCHEMBL7237495 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL4380145 | 0.86 | ALDH1A1 (0.52) | HCAR2ALDH1A1LMNAESR1TSHR | |
| Hydrochloric Acid SCHEMBL213809 | 0.86 | ALDH1A1 (0.52) | HCAR2ALDH1A1LMNAESR1TSHR | |
| Hydrochloric Acid SCHEMBL4731637 | 0.86 | ALDH1A1 (0.52) | HCAR2ALDH1A1LMNAESR1TSHR | |
| SCHEMBL13785332 | 0.85 | CHRNB2 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL23510790 | 0.85 | NAAA (0.50) | HCAR2ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | RECLUDIX PHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025103477-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2025-05-22 | — | — | WO | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2005066189-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| EP-0382463-B1 | Maleimide compounds and fungicides containing them | SUNTORY LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| US-5039696-A | Maleimide derivatives and fungicides for agriculture and horticulture containing the same | SUNTORY LIMITED (JP) | 1991-08-13 | — | — | US | disclosed |
| EP-0382463-A1 | Maleimide compounds and fungicides containing them | SUNTORY LIMITED (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0326799-A2 | Enzymatic process for synthesizing peptides | Degussa Aktiengesellschaft (DE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0313909-A2 | Process for the preparation of phenyl alanine-n-propyl ester hydrochloride | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | CHRNB4 3551/4885CHRNA3 2212/4885GRIN2D 3287/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | CHRNB4 1642/4885CHRNA3 1783/4885GRIN2D 3663/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | CHRNB4 3552/4885CHRNA3 3766/4885GRIN2D 4821/4885 |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | STAT6, STAT5A, STAT3 | CHRNB4 2886/4885CHRNA3 1590/4885GRIN2D 4532/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CHRNB4 4844/4885CHRNA3 4793/4885GRIN2D 4632/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | CHRNB4 2628/4885CHRNA3 2915/4885GRIN2D 4694/4885 |
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | CHRNB4 4692/4885CHRNA3 4662/4885GRIN2D 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.